Global Therapeutic Hypothermia Systems Market Size, Share & Trends Analysis Report By Application (Neurology, Cardiology, Neonatal Care, and Others), By Product (Cooling Devices, Cooling Catheters, and Cool Caps), By Regional Outlook and Forecast, 2023 -

Global Therapeutic Hypothermia Systems Market Size, Share & Trends Analysis Report By Application (Neurology, Cardiology, Neonatal Care, and Others), By Product (Cooling Devices, Cooling Catheters, and Cool Caps), By Regional Outlook and Forecast, 2023 - 2030

The Global Therapeutic Hypothermia Systems Market size is expected to reach $423.6 million by 2030, rising at a market growth of 5.7% CAGR during the forecast period.

North America has seen a growing adoption of therapeutic hypothermia, especially in critical care settings. Therefore, the North America segment captured $110.9 million revenue in the market in 2022. The treatment's effectiveness in post-cardiac arrest care and neurological conditions has contributed to its acceptance in hospitals and healthcare facilities across the region. Owing to these factors, there will be increased demand in the segment.

Therapeutic hypothermia has been recognized as an effective intervention for reducing the risk of brain injury in newborns who have experienced perinatal asphyxia. The primary goal of therapeutic hypothermia in neonatology is to mitigate the extent of brain injury in newborns. By lowering the infant's body temperature, usually to around 33-34 degrees Celsius, therapeutic hypothermia slows down metabolic processes, reduces inflammation, and helps protect brain cells from damage caused by oxygen deprivation. In addition, the increasing incidence of neonatal encephalopathy has led to a growing body of clinical evidence supporting the efficacy of therapeutic hypothermia in improving outcomes for affected infants. Additionally, therapeutic hypothermia, also known as targeted temperature management, is recommended as a specific care strategy for individuals who have experienced cardiac arrest. The objective is to modulate body temperature intentionally to achieve hypothermia, typically 32-36 degrees Celsius, for a specified duration. One of the primary goals of inducing therapeutic hypothermia post-cardiac arrest is to improve neurological outcomes. Cardiac arrest can lead to cerebral ischemia and reperfusion injury, resulting in brain damage. Lowering body temperature helps mitigate the extent of neurological damage, potentially preserving cognitive function and reducing the risk of long-term neurological deficits. Thus, these factors will assist in the expansion of the therapeutic hypothermia systems market.

However, the therapeutic hypothermia process demands meticulous temperature management to achieve the desired therapeutic effects. However, the clinical complexities associated with individual patient characteristics, comorbidities, and response variations pose challenges in maintaining consistent and precise temperature control. Variations in patient response to therapeutic hypothermia introduce uncertainties and challenges. Factors like age, pre-existing medical conditions, and the nature of the underlying injury or illness can lead to diverse responses, making it difficult to establish standardized protocols for temperature modulation. Additionally, effective therapeutic hypothermia necessitates advanced monitoring systems to continuously assess the patient's temperature, vital signs, and neurological status. The requirement for sophisticated monitoring equipment increases the complexity of implementing these systems, adding challenges in terms of accessibility and integration. Thus, these factors will lead to reduced demand for therapeutic hypothermic systems.

By Application Analysis

On the basis of application, the therapeutic hypothermia systems market is divided into neurology, cardiology, neonatal care, and others. In 2022, the cardiology segment witnessed a substantial revenue share in the therapeutic hypothermia systems market. Ongoing research and clinical trials continue to provide supporting evidence for the efficacy of therapeutic hypothermia in improving neurological outcomes after cardiac arrest. Positive research outcomes contribute to the growth of the cardiology segment within therapeutic hypothermia systems as healthcare providers seek evidence-based practices for post-cardiac arrest care. Therefore, these factors will assist in the growth of the segment.

By Product Analysis

Based on product, the therapeutic hypothermia systems market is segmented into cooling devices, cooling catheters, and cool caps. The cooling devices segment held the largest revenue share in the therapeutic hypothermia systems market in 2022. Innovations in device design, materials, and temperature control mechanisms contribute to developing more efficient and precise cooling devices. Manufacturers continually refine their products to enhance performance, reduce energy consumption, and improve patient comfort during therapeutic hypothermia. These factors will boost the demand in the segment.

By Regional Analysis

By region, the therapeutic hypothermia systems market is segmented into North America, Europe, Asia Pacific, and LAMEA. In 2022, the Europe segment acquired a considerable revenue share in the therapeutic hypothermia systems market. The quality of healthcare infrastructure in European countries can influence the adoption of advanced medical technologies. Well-established healthcare systems may be more likely to integrate therapeutic hypothermia into standard medical practices. Thus, these aspects will pose lucrative growth prospects for the segment.

Recent Strategies Deployed in the Market

• Dec-2023: Terumo Medical Corporation, a subsidiary of Terumo Corporation, launched the AZUR HydroPack Peripheral Coil System. The new product is a universal-shaped platinum and hydrogel coil that is used to fill an empty space within the vessel. Additionally, the new product offers precise delivery and optimized stability.
• Jul-2023: ZOLL Medical Corporation, a subsidiary of Asahi Kasei Corporation, came into an agreement with BrainCool AB, an innovative medical device company. Under this agreement, ZOLL Medical enhanced its temperature management solutions product portfolio to include intravascular technology and surface options. Additionally, the agreement provided clinicians with advanced solutions with precise temperature control.
• Dec-2021: Becton, Dickinson, and Company completed the acquisition of Venclose, Inc., a medical technology company developing solutions for the treatment of chronic venous insufficiency. Through this acquisition, Becton, Dickinson, and Company offered a variety of solutions to physicians for the treatment of venous conditions.
• Jun-2021: ZOLL Medical Corporation, a subsidiary of Asahi Kasei Corporation, entered into an agreement with Global Healthcare SG, a medical technology organization. Under this agreement, the companies distributed CarbonCool Full Body Suit and Comfort Suit in the Asia-Pacific countries.
• Jul-2020: Terumo Corporation completed the acquisition of Quirem Medical B.V., a Netherlands-based healthcare startup. Through this acquisition, Terumo strengthened its manufacturing and clinical development activities. Additionally, the acquisition provided a variety of products that will support the customers.

List of Key Companies Profiled

• Asahi Kasei Corporation
• Becton, Dickinson, and Company
• Gentherm Incorporated
• Stryker Corporation
• Belmont Medical Technologies(Audax Management Company, LLC)
• EM-MED Sp. z o.o. Sp. K.
• International Biomedical Ltd.
• Phoenix Medical Systems Pvt. Ltd.
• Shenzhen Comen Medical Instruments Co., Ltd.
• Terumo Corporation

Global Therapeutic Hypothermia Systems Market Report Segmentation

By Application

• Neurology
• Cardiology
• Neonatal Care
• Others

By Product

• Cooling Devices
• Cooling Catheters
• Cool Caps

By Geography

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific
• LAMEA
• Brazil
• Argentina
• UAE
• Saudi Arabia
• South Africa
• Nigeria
• Rest of LAMEA